1-9 of 9
Martin Reck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Y. Jin, Michael L. Maitland, Martin Reck, Mark A. Socinski
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4314.
https://doi.org/10.1158/1078-0432.CCR-23-2525
Published: 13 October 2023
View article titled, Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
Open the PDF for Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150 in another window
Journal Articles

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Y. Jin, Michael L. Maitland, Martin Reck, Mark A. Socinski
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1047–1055.
https://doi.org/10.1158/1078-0432.CCR-22-2323
Published: 14 March 2023
View article titled, Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
Open the PDF for Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150 in another window
Includes: Supplementary data
Journal Articles

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H. Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck, for the RELAY study investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5258–5271.
https://doi.org/10.1158/1078-0432.CCR-21-0273
Published: 01 October 2021
View article titled, RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
Open the PDF for RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer

Steffen Dietz, Petros Christopoulos, Lisa Gu, Volker Endris, Zhao Yuan, Simon J. Ogrodnik, Tomasz Zemojtel, Marc A. Schneider, Anna-Lena Volckmar, Michael Meister, Thomas Muley, Martin Reck, Matthias Schlesner, Michael Thomas, Albrecht Stenzinger, Holger Sültmann
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A21.
https://doi.org/10.1158/1557-3265.LiqBiop20-A21
Published: 01 June 2020
View article titled, Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer
Journal Articles

Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer

David F. Heigener, Keith M. Kerr, Gavin M. Laing, Tony S.K. Mok, Fedor V. Moiseyenko, Martin Reck
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4881–4887.
https://doi.org/10.1158/1078-0432.CCR-18-1894
Published: 15 August 2019
View article titled, Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer
Open the PDF for Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer in another window
Journal Articles

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

Suresh S. Ramalingam, Normand Blais, Julien Mazieres, Martin Reck, C. Michael Jones, Erzsebet Juhasz, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Keiholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dziubinski, Hao Xiong, Peter Ansell, Mark McKee, Vincent Giranda, Vera Gorbunova
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1937–1944.
https://doi.org/10.1158/1078-0432.CCR-15-3069
Published: 13 April 2017
View article titled, Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Open the PDF for Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Anish Thomas, Ira Pastan, Jeff Parno, Daniel J. O'Shannessy, Penny Fatato, Julia D. Maltzman, Bruce A. Wallin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5927–5936.
https://doi.org/10.1158/1078-0432.CCR-14-0804
Published: 30 November 2014
View article titled, Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Open the PDF for Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

Enriqueta Felip, Federico Rojo, Martin Reck, Astrid Heller, Barbara Klughammer, Gemma Sala, Susana Cedres, Sergio Peralta, Heiko Maacke, Dorothee Foernzler, Marta Parera, Joachim Möcks, Cristina Saura, Ulrich Gatzemeier, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3867–3874.
https://doi.org/10.1158/1078-0432.CCR-07-5186
Published: 16 June 2008
View article titled, A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
Open the PDF for A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy in another window
Journal Articles

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Denis C. Talbot, Joachim von Pawel, Emma Cattell, S. Murray Yule, Claire Johnston, Anthe S. Zandvliet, Alwin D.R. Huitema, Chris J. Norbury, Paul Ellis, Leon Bosquee, Martin Reck
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1816–1822.
https://doi.org/10.1158/1078-0432.CCR-06-0249
Published: 15 March 2007
View article titled, A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer in another window